This opportunity is currently closed.
Sign up for Content alerts to stay informed when this or related funding opportunities are posted.
Development and Validation of Models for Alzheimers Disease-Related Dementias (ADRD) (R61/R33 – Clinical Trial Not Allowed)
The Development and Validation of Models for Alzheimers Disease-Related Dementias (ADRD) (R61/R33 - Clinical Trial Not Allowed) research funding program from the National Institutes of Health supports the development and validation of clinically relevant models of AD/ADRD including post-TBI dementias. Models could include small animals, larger animals, ex vivo models, human iPSCs, or other in vitro models. Validation includes internal, face, construct, and predictive (to the extent possible) validation. Such validations could include looking at underlying mechanism/pathways, functional imaging, behavior, and other cognitive readouts. Independent replication is also encouraged. These models can be developed/validated with the goal of supporting therapy development or better understanding of human disease mechanisms and mechanisms that uncover predisposition to developing neurodegenerative dementias. Either way, it is essential that models reflect the human condition as much as possible. Novel models of complex pathology or comorbid conditions are encouraged. Such models could include multiple manipulations (genetics, environment, lifestyle, age, etc.) to better reflect the complex interaction of risk factors in patients. New models need to be innovative and address a gap in the currently available models. The R61 phase will support initial development, internal validation and optimization of the model. The R33 phase will support external validation studies. The outcome should be a fully validated model. Applications are open researchers at US-based research institutions. Applicants may apply for up to 600,000 USD/year for up to 5 years.
Opportunity ID: PAR-23-154.
Letters of intent are due on September 20, 2023 and full applications are due on October 20, 2023.
October 20, 2023